Sino Biopharmaceutical (FRA:SMZ1) Buildings And Improvements : €586 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Sino Biopharmaceutical Buildings And Improvements?

Sino Biopharmaceutical's quarterly buildings and improvements declined from Dec. 2022 (€572 Mil) to Jun. 2023 (€0 Mil) but then increased from Jun. 2023 (€0 Mil) to Dec. 2023 (€586 Mil).

Sino Biopharmaceutical's annual buildings and improvements increased from Dec. 2021 (€545 Mil) to Dec. 2022 (€572 Mil) and increased from Dec. 2022 (€572 Mil) to Dec. 2023 (€586 Mil).

Sino Biopharmaceutical Buildings And Improvements Historical Data

The historical data trend for Sino Biopharmaceutical's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Buildings And Improvements Chart

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buildings And Improvements

Get a 7-Day Free Trial

374.28

495.77

545.45

571.60

586.27

Sino Biopharmaceutical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Buildings And Improvements	Get a 7-Day Free Trial															545.45	-	571.60	-	586.27

Sino Biopharmaceutical Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Sino Biopharmaceutical (FRA:SMZ1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (FRA:SMZ1) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

SBHMY:USA SBMFF:USA 01177:Hong Kong SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (FRA:SMZ1) Headlines

No Headlines